This article is more than 5 years old. Information may no longer be current.

Imprimis reports 508% increase in revenue in third quarter

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Imprimis Pharmaceuticals reported $2.7 million in total revenue in the third quarter, a 508% increase from $0.4 million reported in the same quarter of 2014, according to a press release.

Sales for Tri-Moxi and Tri-Moxi-Vanc compounded injectable formulations were reported at  $594,000 in the third quarter. Sales for combination topical eye drop formulations were reported at  $263,000.

Net loss was reported at $3.9 million, or $0.41 per share, in the third quarter compared with a net loss of $2.4 million, or $0.27 per share, in the same quarter of 2014.

Selling and marketing expenses were reported at $1.8 million in the third quarter compared with $637,000 in the same quarter of 2014.